Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Hepatectomy

Research Leaders

6 sponsors active, led by The First Hospital of Jilin University

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Unknown2
Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT06230328Completed

Brazilian Reality of Hepatocellular Carcinoma

NCT06559761RecruitingPrimary

Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research

NCT05125094UnknownPrimary

Prognostic Performance of Preoperative and Follow by Gadoxetic Enhanced MRI in HCC Patients After TACE

NCT04961138Not ApplicableUnknownPrimary

Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma

Showing all 4 trials

Research Network

Common Treatments

  • Hepatectomy1
  • Transhepatic Arterial Chemotherapy And Embolization Tace1
  • Surgery1
  • Taceablation1

Active Sponsors

  • The First Hospital of Jilin University1
  • Chinese PLA General Hospital1
  • Hospital Israelita Albert Einstein1
  • AstraZeneca1
  • Second Affiliated Hospital, Zhejiang University, School of Medicine1

Top Investigators

Related Conditions

  • Hepatocellular Carcinoma Stage Ii1
  • Hepatocellular Carcinoma By Bclc Stage1
  • Hepatocellular Carcinoma Stage I1
  • Hepatocellular Carcinoma1

Activity Timeline